The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COMy 2020 | The importance of MRD in multiple myeloma management
Jesus San Miguel, MD, Universidad de Navarra, Navarra, Spain, highlights the importance of measurable residual disease (MRD) in the management of multiple myeloma. The use of MRD supersedes conventional complete response criteria. MRD can predict the outcome of newly diagnosed patients and those in relapse. Different labs all over the world have confirmed the benefits of using MRD as a prognostic factor. This interview took place during the Controversies in Multiple Myeloma (COMy) 2020 Virtual World Congress.
Disclosures
Consulting or Advisory role for Amgen, BMS, Celgene, Janssen, MSD, Novartis, Takeda, Sanofi, Roche, GSK, Abbvie and Karyopharm.
